August 22, 2012
GlaxoSmithKline plc (GSK) of the UK has announced that its anticancer agent pazopanib (brand name overseas: Votrient) has been approved for the treatment of patients with advanced soft tissue sarcoma (aSTS), who have received prior chemotherapy or have progressed within...read more